Advertisement
Advertisement
At close: 05:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 381.02 |
| Open | 380.78 |
| Bid | 381.31 x 1000 |
| Ask | 381.50 x 900 |
| Day's Range | 380.55 - 381.28 |
| 52 Week Range | 219.85 - 381.99 |
| Volume | |
| Avg. Volume | 1,703,123 |
| Market Cap | 17.181B |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | 77.13 |
| EPS (TTM) | 4.94 |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 363.00 |
- American City Business Journals
J&J completes $16.6B acquisition of local medical device firm
Johnson & Johnson Inc. closed its acquisition of Danvers medical device maker Abiomed Inc. on Thursday. The deal weighed in at $16.6 billion, making it easily one of the largest acquisitions of the year.
- Zacks
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
- Business Wire
FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
